Skip to main content

Scotland’s economy: Brexit ‘brain drain’ warning for tech firms

Employers in the field of digital technologies have been urged to start planning how to retain European Union workers following Brexit.

In its latest briefing ahead of the UK’s departure from the EU, trade body ScotlandIS said the industry is already facing a skills shortage and firms should take steps now to ensure they still have access to those with the best talents.

• READ MORE: Brexit ushers in more competition for skilled staff

Scotland’s software and IT businesses alone employed 4,000 non-UK EU nationals in 2015, accounting for 11.5 per cent of the workforce.

Lynne Marr, an employment law specialist and partner at legal firm Brodies, which worked with ScotlandIS on the briefing, said companies should start by reviewing the residency status of all employees, and organise sessions with immigration law experts “to provide their staff with objective information on their options”.

She added: “There are plans for the UK government to bring forward an immigration bill setting out a framework for a new immigration system. Different options are being discussed and it is possible that a whole new system for EU and non-EU citizens could be designed.”

• READ MORE: Scotland’s digital tech sector poised for growth

ScotlandIS research and policy manager Svea Miesch said: “Understandably the future status and rights of EU nationals living and working in the UK is a subject of particular importance and concern for our members. Many of Scotland’s digital technologies companies employ staff from other EU countries but that is not the only issue. We have companies that are owned by non-UK EU nationals, and EU students studying at Scottish universities are an important source of future talent for our industry.

“It’s important to note that nothing will change until at least March 2019 when the UK leaves the EU. Until then, the UK has to guarantee freedom of movement for citizens of other EU countries.”

ScotlandIS said it was developing proposals on a future immigration system that would serve the needs of Scotland’s digital technologies industry and “allow businesses to continue to thrive”.

Miesch said: “We are keen to hear from our members and others in the business community with suggestions and experiences of hiring and retaining international talent in Scotland’s digital economy.”

IT recruitment specialist Cathcart Associates was the exclusive recruitment partner at the recent Digit IT Leaders conference, held at Edinburgh’s Dynamic Earth.

Managing director Gordon Kaye said: “Conferences like these are a brilliant opportunity for everyone to come together and learn from one another.”

Click here to ‘Like’ The Scotsman Business on Facebook

Go to Source

Solar Firms Plan To Return To Nevada After New Law Restores Incentives

Enlarge this image

Nevada Gov. Brian Sandoval plans to sign a bill will let homeowners with solar panels sell excess electricity to their utility at retail rates, his office says.

Drew Angerer/Getty Images


hide caption

toggle caption

Drew Angerer/Getty Images

Some of Nevada’s largest solar installation companies plan to resume doing business in the state. For the past year-and-a-half Tesla (formerly SolarCity) and Sunrun stopped seeking new customers in this sunny part of the country because the state’s Public Utilities Commission chose to phase out incentives for homeowners who install rooftop solar panels.

Now, Republican Gov. Brian Sandoval plans to sign into law a bill that brings back “net metering.”

Net metering has been a key reason for the rapid growth of the residential solar power business across the U.S. It allows homeowners with solar panels to sell excess electricity to their utility at retail instead of wholesale rates. This appeals to many homeowners because they can do something good for the environment and save money on their energy bill.

Utilities are not fans of net metering. That’s because every kilowatt generated on a home roof is one less that the local utility sells. And some of that money utilities collect is used to maintain the electric grid.

In arguing against Nevada’s net metering system last year, the state’s largest utility, NV Energy, echoed an argument that utilities across the country make. Berkshire Hathaway owns the utility and CEO Warren Buffet said on CNBC that when solar customers don’t pay to maintain the grid, non-solar customers are left to pick up the tab.

Utilities like NV Energy argue that amounts to a subsidy for homeowners with solar panels. Solar advocates say the utilities are just trying to protect their monopolies.

The new legislation in Nevada strikes a compromise. Homeowners with solar panels on their roof will be able to sell any excess electricity their household doesn’t use to the utility, but at a reduced rate. Currently that’s 95 percent of the retail rate. That number will go down as more rooftop solar systems are installed in the state. The Nevada law also creates new protections for homeowners, such as a guaranteed net metering rate for 20 years.

“Nevada is one step closer to a policy that will allow it to get back thousands of solar jobs that were lost,” says Sean Gallagher, vice president of state affairs for the Solar Energy Industries Association. The SEIA estimates more than 2,600 jobs were lost when the large solar companies stopped doing business in Nevada.

Sandoval’s office tells NPR the governor plans to sign the new bill into law next week.

Go to Source

China firms, foreign funds seen as bidders for Eletrobras, Cemig assets

By Luciano Costa
| SAO PAULO

Chinese power utilities and foreign investment funds are seen as the likely bidders in upcoming asset sales in Brazil’s electricity industry, as debt-laden state utilities seek to root out years of political mismanagement and balance sheet overstretching, according to lawyers familiar with the market.

Centrais Elétricas Brasileiras SA (ELET6.SA), known as Eletrobras, and Cia Energética de Minas Gerais SA (CMIG4.SA), known as Cemig, plan to divest generation and transmission assets, including their stakes in some of Brazil’s largest hydroelectric dams – Santo Antônio and Belo Monte.

Large Chinese strategic investors will probably be the winning bidders for the dams, because the size of the projects fit their strategies better and they would be willing to pay more, said Tiago Figueiró, who is part of the team involved in electricity industry issues at São Paulo-based law firm Veirano Advogados.

“It would be pretty hard to attract an American or European investor for a project of that size,” he said.

Chinese power conglomerates have gradually become the dominant force in Brazil’s electricity industry, where high debt, a harsh recession and less stringent takeover barriers than in other major markets have stoked a wave of acquisitions.

Eletrobras and Cemig are planning the divestitures in order to cut debt and cushion themselves from the impact of the harshest recession on record in Brazil, Latin America’s largest economy.

Since the start of 2015, Chinese companies have been the buyers in most announced electricity mergers in Brazil, according to Thomson Reuters deals intelligence data.

Brazil has been the No. 1 M&A global destination for China’s State Grid Corp [STGRD.UL], the world’s largest utility, since 2010, accounting for 43 percent of the $37 billion it spent on acquisitions during that period, Thomson Reuters data showed.

For China Three Gorges Corp [CYTGP.UL], a power generator which owns the Three Gorges dam, the world’s second largest, Brazil acquisitions represented 19 percent of its $30.6 billion worth of M&A deals in the same period.

José Oliva, a lawyer at São Paulo-based Pinheiro Neto Advogados, said the Eletrobras and Cemig asset sale plans are unlikely to be much affected by ongoing political turmoil in Brazil, as power sector acquisitions are perceived as a long-term investment.

Cemig, which is controlled by the Brazilian state of Minas Gerais, has included wind farms and small power dams in a divestiture plan worth 6.5 billion reais ($1.83 billion).

Eletrobras – Brazil’s largest power holding company – is selling stakes in more than 100 projects, from which it could fetch around 5 billion reais.

Bankers, lawyers and industry executives expect that European and North American investment and pension funds may bid for the minority stakes that Eletrobras and Cemig have in smaller projects such as power transmission lines and renewable energy firms.

Paulo Dalla Nora, an asset manager at FIR Capital, says he has already seen interest from foreign investors, particularly in renewable energy assets.

(Writing by Marcelo Teixeira; Editing by Guillermo Parra-Bernal and Leslie Adler)


Go to Source

City asks Albany to let it hire firms owned by women and minorities more easily

The de Blasio administration is seeking state legislation that would help the city hire more contractors owned by women and minorities, said Deputy Mayor Richard Buery, who is spearheading the effort. 

State law limits the size of contracts the city can dole out as discretionary spending, among other constraints that Buery argues hamper the administration’s ability to spend money at such businesses. A state bill would lift the ceiling to $200,000—the same ceiling that state government has—from $20,000. It would also allow the creation of pre-qualified lists of minority and women-owned enterprises, MWBEs, meaning the firms could gain work without filing cumbersome proposals for every job. 

“Businesses, they may have the know-how, they can do the work, but they may be new to city contracting, they may be inexperienced when it comes to how to compete for a bid, or frankly, the work might be too small for it to be worthwhile for a small business that didn’t have a big administrative infrastructure” to do all the required paperwork, Buery told Crain’s.

article continues below advertisement

The bill would also enable the city to set up a mentoring program and to choose contractors who do not offer the lowest bids on projects.

“Having this type of increase in discretion has to work hand-in-hand with a cultural change across agencies, to work with agencies to improve their procurement processes,” Buery said. “It has to work hand-in-hand with ambitious procurement goals around minority and women-owned businesses. All these things have to work together in lock-step. And again, if we had all these tools … that’s how you unleash opportunity.”

The city spends $15 billion to $17 billion on procurement annually, officials said. Of that, roughly a third is subject to the city’s MWBE targets (for example, contracts for nonprofits don’t count). The administration aims to contract out 30% of the value of that work to MWBEs by 2021, up from about 19% today. It contracted $696 million of work to MWBEs, about 14%, in fiscal 2016, and 8% in the previous year.

The Building Trades Employers Association, which released a study earlier this week describing a shortage of MWBEs that can fulfill city construction contracts, opposes the bill. The industry group cited the legislation’s low-bidder provision and prequalification list components, and said the measure should apply to all city and state agencies. BTEA does support the mentoring program piece.

“We look forward to working with the city on having this legislation passed with respect to the mentoring language as we believe that is a key to increasing the capacity of MWBE companies to win contracts, and working to amend the bill in the ways we outlined in our report,” BTEA President and CEO Louis Coletti said in an email.

The Senate bill is sponsored by Marisol Alcantara and Diane Savino, two city members of the Independent Democratic Conference, which caucuses with the Republicans. That affiliation enhances the chances of the bill passing the Senate but is a source of rising tension in the city.

Go to Source

Five more firms picked for fast-track restructuring program

Five South Korean firms received government approval to carry out their voluntary corporate restructuring through fast-track legal and administrative procedures, the industry ministry said Thursday.

The Ministry of Trade, Industry and Energy said a government panel chose five companies, including LG Siltron Inc., which manufactures wafers for semiconductors; ITC Co., a cable supplier; and Shin Pung Textile Co. to endorse their proposed restructuring efforts to boost competitiveness.

(Yonhap)

With the latest addition, there are now 37 companies subject to the “one-shot” act, as part of the Seoul government’s efforts to speed up corporate restructuring in struggling industries, including shipbuilding, steel and petrochemicals.

LG Chem, the country’s largest chemicals manufacturer, and Hanwha Chemical have also been included on the government-backed list.

The ministry said LG Siltron will sell its old lines and expand facilities for high-end semiconductors, while ITC and other selected companies will take steps to diversify their business portfolios.

The law came into effect in August last year to help businesses conduct intracorporate mergers and spinoffs through simplified procedures that included exemptions from strict antitrust laws and financial market regulations. They will also be given tax benefits and subsidies for research and development on corporate restructuring.

Local companies that want to benefit from the fast-track corporate restructuring procedures are required to win government approval. (Yonhap)

Go to Source

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of John Wood Group PLC – WDGJF

NEW YORK, NY / ACCESSWIRE / June 7, 2017 / Pomerantz LLP is investigating claims on behalf of investors of John Wood Group PLC (“John Wood” or the “Company”) (OTC PINK: WDGJF). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

The investigation concerns whether John Wood and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here to join a class action]

On May 23, 2017, in a prospectus concerning the Company’s proposed acquisition of Amec Foster Wheeler (“Amec”), John Wood disclosed details of the Company’s internal probe into its past dealings with Unaoil, a Monaco-based oil business under criminal investigation by the U.K.’s Serious Fraud Office (“SFO”). John Wood further disclosed that the SFO had requested that Amec produce information related to the agency’s investigation into Unaoil.

On this news, John Wood’s share price fell $0.38, or 3.93%, to close at $9.30 on May 25, 2017.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

SOURCE: Pomerantz LLP

ReleaseID: 465115

NEW YORK, NY / ACCESSWIRE / June 7, 2017 / Pomerantz LLP is investigating claims on behalf of investors of John Wood Group PLC (“John Wood” or the “Company”) (OTC PINK: WDGJF). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

The investigation concerns whether John Wood and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here to join a class action]

On May 23, 2017, in a prospectus concerning the Company’s proposed acquisition of Amec Foster Wheeler (“Amec”), John Wood disclosed details of the Company’s internal probe into its past dealings with Unaoil, a Monaco-based oil business under criminal investigation by the U.K.’s Serious Fraud Office (“SFO”). John Wood further disclosed that the SFO had requested that Amec produce information related to the agency’s investigation into Unaoil.

On this news, John Wood’s share price fell $0.38, or 3.93%, to close at $9.30 on May 25, 2017.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

SOURCE: Pomerantz LLP

ReleaseID: 465115

Source URL: http://marketersmedia.com/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-john-wood-group-plc-wdgjf/205926

Source: AccessWire

Release ID: 205926

Go to Source

Health Law Debate Deflects The Heat Away From Pharma

News outlets report on stories related to pharmaceutical pricing.

Morning Consult:
With Spotlight On Obamacare, Public’s Opinion Of Drugmakers Softens

Consumer perceptions of several major pharmaceutical companies have softened in recent months amid an industry push to counter public uproar over high drug prices, Morning Consult Brand Intelligence data show. Large drugmakers this spring have seen a decline in the the percentage of Americans who view them unfavorably, according to weekly national surveys of thousands of U.S. adults. (Reid, 6/5)

Stat:
This Insulin Maker Is Running Out Of Money. Its Solution? Reality TV

The drug manufacturer MannKind has been burning through millions of dollars each month. It only has 3,000 patients taking its sole product, an inhalable form of insulin. It recently said it doesn’t have enough cash to get to the end of this year. So why, then, is the company sponsoring a reality TV show filmed here in this tropical resort town? … Don’t expect the competitions typical of the genre: No one got voted off the island (though one cast member dramatically quit the show), and no one competed for a prize. Their goal is to turn their health around, with the help of lessons on everything from reading nutritional labels to recognizing a safe range for blood sugar levels. (Robbins, 6/5)

ProPublica:
A Drug Quintupled in Price. Now, Drug Industry Players Are Feuding Over the Windfall.

Amid public concern over spiking drug prices, a powerful middleman is suing a tiny drugmaker over unpaid rebates and fees. The maker calls the suit baseless; analysts say the suit offers a window into an opaque world. (Ornstein and Thomas, 6/1)

The Associated Press:
Insider Q&A: Drug Industry Learns To Listen To Patients

Drugmakers are finding they can improve how drug testing is conducted— and help their own bottom lines — by giving patients a voice before testing even begins. Pharmaceutical companies sometimes spend more than a decade trying to win approval for a new medicine, including running multiple rounds of tests on hundreds and even thousands of people. Now they are realizing that treating study participants better and listening to their concerns and insights can make the complicated process cheaper, produce results that are more accurate and help get drugs to market faster. (Johnson, 6/4)

Stat:
AMA Will Vote On Requiring Drug Prices In Consumer Ads

In its latest bid to restrain pharmaceutical advertising, the American Medical Association will vote on a resolution to demand that drug makers disclose pricing in ads that are aimed at consumers.The proposal, which will be heard at the annual AMA meeting next week in Chicago, was made in response to concerns over rising drug costs and an unsuccessful bid by the medical organization to convince Congress to ban so-called direct-to-consumer advertising altogether. An AMA spokesman wrote us that this appears to be the first time AMA delegates will consider such a resolution. (Silverman, 6/6)

Stat:
U.S. Could Save $825 Million From A Small Change In Immunotherapy Dosing, Study Says

Aflick of the prescriber’s pen could save $825 million a year on lung cancer care in the U.S. That’s the finding of a new study on the immunotherapy drug pembrolizumab, marketed commercially as Keytruda by Merck. By switching to weight-based dosing — instead of a fixed dose of 200 mg — doctors could quickly reduce costs of the intravenous therapy without compromising its effectiveness, the study concludes. The finding could lead to changes in care for thousands of U.S. patients with lung cancer, which kills about 158,000 Americans a year. (Ross, 6/3)

Kaiser Health News:
Daylight On Diabetes Drugs: Nevada Bill Would Track Insulin Makers’ Profits

Patients notched a rare win over the pharmaceutical industry Monday when the Nevada Legislature revived a bill requiring insulin makers to disclose the profits they make on the life-sustaining drug. In a handful of other states, bills addressing drug prices have stalled. Many of the 1.25 million Americans who live with Type 1 diabetes cheered the legislative effort in Nevada as an important first step in their fight against skyrocketing costs of a drug on which their lives depend. The cost of insulin medications has steadily risen over the past decade by nearly 300 percent. (Kopp, 6/7)

The Wall Street Journal:
Study Questions Value Of Costly Cancer-Drug Combinations

A new study is stirring debate about whether the benefits of cancer drugs are worth their cost, particularly as drugmakers develop treatments that combine multiple pricey drugs. The study of about 4,800 women with an aggressive type of breast cancer found that adding Roche Holding AG’s drug Perjeta to the company’s older treatment Herceptin conferred a slight benefit versus Herceptin alone, after the women had undergone surgery to remove tumors. (Loftus, 6/5)

Stat:
Spending On Cancer Drugs Is Forecast To Rise In The Single Digits

The growth in the price of cancer medicines in the U.S. averaged 3.6 percent last year, a drop from 4.7 percent in 2015, after accounting for rebates and discounts that drug makers paid to health insurers, according to a new report. Meanwhile, the plethora of new cancer drugs is projected to generate increased spending of 6 percent to 9 percent annually through 2021, when global costs are forecast to exceed $147 billion, which is in keeping with the nearly 9 percent compounded annual spending growth rate that was seen over the past five years, according to the market research arm of QuintilesIMS. (Silverman, 6/1)

Stat:
More Health Plans Eye Deals For Drugs Based On Outcomes

As the cost of prescription drugs remains vexing, a new survey finds that more health plans are increasingly interested in paying for the highest-priced medicines based on patient outcomes. And the findings suggest that insurers are eager to exploit drug makers that are willing to strike such deals in order to win favorable insurance coverage. In these arrangements, a health plan may get an extra discount from a drug maker if a medicine does not help patients as much as expected, or a drug maker may get a credit toward a rebate provided to a health plan. The survey, released last week, found interest was particularly strong for hepatitis C and oncology drugs, although plans have started to use these arrangements for other types of drugs, as well. (Silverman, 6/1)

Bloomberg:
Roche’s Pricey New Breast-Cancer Combo Barely Beats Old Drug

Roche Holding’s new breast cancer combination therapy barely outperformed a current gold-standard drug for the disease — the company’s own decades-old Herceptin — in its latest study. The results, presented Monday in Chicago at the world’s largest gathering of cancer researchers, are a disappointment and probably won’t justify moving a majority of patients to Roche’s pricey new combo treatment, doctors say. Researchers had warned that it would be tough to top Herceptin, which revolutionized treatment for women with an aggressive type of breast cancer called HER2-positive after Roche introduced it in 1998. (Kresge, 6/6)

Stat:
Failure To Warn: An Early Warning System For Drug Risks Falls Flat

In 2007, after a number of dangerous medicines were pulled off the market, Congress ordered the Food and Drug Administration to set up an early warning system to detect other harmful drugs before more people died. The FDA responded by creating a system called the Sentinel Initiative, which mines insurance data and medical records to identify possible risks. But a system that was touted as a revolutionary way to glean valuable information from electronic health records and protect patients has had little measurable impact, according to a STAT examination and interviews with drug safety experts. Ten years and $207 million later, critics question whether Sentinel can adequately identify risks involving drugs that are already in consumers’ medicine cabinets. (Kaplan, 6/6)

The Washington Post:
Before Price Gouging Law Takes Effect, Advocates Hunt For Evidence To Enforce It

Months before it takes effect, advocates are collecting ammunition to enforce Maryland’s new law against prescription drug- price gouging. The Maryland Citizens Health Initiative launched a website Sunday to collect examples of price increases that could potentially be used to build future cases against drug companies after the law takes effect in October. (Cox, 6/4)

The Wall Street Journal:
What’s Behind The Biotech Sector’s Rebound

Biotech stocks took a pounding in 2016 but have bounced back since, with a range of exchange-traded funds benefiting from the resurgence. The biotechnology sector harnesses biological processes to create technologies and products for a wide variety of challenges, from expanding crop sizes to treating disease. Pharmaceutical-focused firms are a major component of biotech funds, with names like Celgene Corp. and Gilead Sciences Inc. often among their top 10 holdings. (Cowan, 6/4)

Stat:
Nevada Governor Is Willing To Sign Revised Diabetes Drug Pricing Bill

In a blow to the pharmaceutical industry, Nevada Gov. Brian Sandoval says he is willing to support revised legislation that is designed to contain the cost of diabetes drugs. The bill will require drug makers to report pricing histories, disclose costs, notify state officials and insurers in advance of price hikes above inflation, and report rebates paid to pharmacy benefit managers, the middlemen that negotiate favorable insurance coverage. In addition, PBMs will also have to disclose rebates paid to health plans. (Silverman, 6/5)

The Associated Press:
Drug Price Cap Fight Intensifies As Issue Heads To Fall Ballot

Debate is heating up over an initiative headed to Ohio’s fall ballot that backers say is aimed at controlling drug prices. The Ohio Drug Price Relief Act is a citizen-initiated statute supported by the California-based AIDS Healthcare Foundation. It seeks to bar state agencies from buying drugs at prices higher than those paid by the U.S. Department of Veterans Affairs, which receives deep discounts. (6/4)

Kaiser Health News:
Many COPD Patients Struggle To Pay For Each Medicinal Breath

After a lifetime of smoking, Juanita Milton needs help breathing. She’s tethered to an oxygen tank 24/7 and uses two drug inhalers a day, including Spiriva, which she called “the really expensive one.” “If I can’t afford it, I won’t take it,” Milton said. (Tribble, 6/5)

Boston Globe:
Vertex Goes All-In On Its Effort To Conquer Cystic Fibrosis

Now comes the hard part for Vertex Pharmaceuticals Inc. After launching two drugs aimed at nearly 40 percent of the 75,000 patients worldwide who suffer from cystic fibrosis, the biotech is mounting an assault on a range of mutations causing the obstructive lung disease in the remaining patients. Until the Vertex medicines hit the market, there was no treatment for the life-threatening condition, which causes serious lung infections that can result in respiratory failure. (Wisman, 6/6)


This is part of the KHN Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.

Go to Source

Major law firms keep refusing meetings to discuss defending Trump

At least four major law firms backed away from talks with the White House to help defend President Trump in the escalating federal Russia probe, citing worries that the headstrong commander-in-chief would not listen to their counsel, Yahoo News reported Tuesday.

Among the lawyers and firms that weren’t interested in representing Trump were Brendan Sullivan of Williams & Connolly, Ted Olson of Gibson, Dunn & Crutcher, Paul Clement and Mark Filip of Kirkland & Ellis, and Robert Giuffra of Sullivan & Cromwell, Yahoo reported.

Olson worked as the solicitor general under former President George W. Bush and served as the judicial committee chair for Rudy Giuliani’s 2008 presidential campaign. Clement followed Olsen as solicitor general under Bush in 2004 Sullivan represented Oliver North during the 1987 congressional hearings regarding the Iran-Contra scandal.

“The concerns were, ‘The guy won’t pay and he won’t listen,’” one of the lawyers familiar with the talks told the outlet.

James Comey to testify before Senate next week about Russia

The number of firms that declined invitations even just to talk about taking on the work signals the overwhelming task of defending the President amid a rapidly expanding probe being run by Special Prosecutor Robert Mueller, as well as concerns some of the nation’s top lawyers appeared to have about the commander-in-chief’s propensity for tweeting.

Trump’s search for an outside attorney ended last month after he announced he was bringing in Marc Kasowitz, one of his longtime personal lawyers, to lead his outside counsel team during the investigation.

Kasowitz has represented Trump several times in the past, including for his divorce proceedings, against fraud allegations for Trump University and in multiple real estate transactions. The New York-based lawyer, however, is notorious for his aggressive and loud style and has raised concerns among Republicans that he could do more harm than help in such a high-profile investigation.

Not Released (NR)

The President is having some issues securing legal help.

(TIZIANA FABI/AFP/Getty Images)

Trump had been advised to seek outside counsel after the Justice Department brought in former FBI Director Robert Mueller as a special prosecutor last month to resume investigating whether members of Trump’s campaign and transition team coordinated with Russian efforts to meddle in the election.

Putin speculates Americans faked election hacking evidence

Former FBI Director James Comey had been leading that investigation until he was fired in May by Trump, who reportedly told Russian diplomats inside the Oval Office that he cut the agency chief explicitly to relieve himself of the “great pressure” he was facing from the probe.

Comey will testify before the Senate Intelligence Committee Thursday, and is expected to divulge further details about the situation.

But the investigation has already touched various members of the Trump administration, including former National Security Adviser Michael Flynn, top aide and son-in-law Jared Kushner and Attorney General Jeff Sessions.

All three had discussions with Russian diplomats before Trump took office.

Trump lawyer Michael Cohen is new focus of Russia investigation

Trump’s decision to bring in Kasowitz won’t limit his ability to rely on White House Counsel Don McGahn, but McGahn’s own involvement in the controversies surrounding Flynn and Comey has raised even more questions.

Former Acting Attorney General Sally Yates, whom Trump fired in January after she refused to defend his first travel ban, testified earlier this month before the Senate Intelligence Committee that she’d warned McGahn on Jan. 26 — three weeks before Flynn resigned — that Flynn’s ties to Russia could put him in a compromising position.

Specifically, she said she told McGahn that Flynn had put himself in a situation where he could be “blackmailed by the Russians” by lying publicly about his private conversations with Russia’s ambassador to the U.S.

It isn’t clear what McGahn did with that information, although White House Press Secretary Sean Spicer has repeatedly claimed that McGahn immediately told Trump of what Yates said and then concluded no criminal activity had occurred.

Russia claimed it had ‘derogatory’ intelligence on Trump

Meanwhile, Trump has also ditched the idea of creating a “war room” staffed with former allies to help defend his administration, Politico reported late Monday.

As recently as last week, talks were still underway to bring in former campaign manager Corey Lewandowski and former deputy campaign manager David Bossie to lead an internal effort to help contain the fallout from the Russia probe and get the White House back on message.

White House officials, however, decided that Kasowitz was best positioned to handle the entire effort, Politico reported.

Tags:
donald trump
russia
fbi
james comey
michael flynn
sally yates
sean spicer
robert mueller
jared kushner
jeff sessions

Send a Letter to the Editor

Join the Conversation:
facebook
Tweet

Go to Source

Four Top Law Firms Rebuffed Trump

“Top lawyers with at least four major law firms rebuffed White House overtures to represent President Trump in the Russia investigations, in part over concerns that the president would be unwilling to listen to their advice,” Yahoo News reports.

“The unwillingness of some of the country’s most prestigious attorneys and their law firms to represent Trump has complicated the administration’s efforts to mount a coherent defense strategy to deal with probes being conducted by four congressional committees as well as Justice Department special counsel Robert Mueller.”

FavoriteLoadingSave to Favorites


Go to Source

Some of America’s top law firms don’t want Donald Trump as a client

One would think that, given President Donald Trump’s increasing need for quality legal assistance in a high-profile scandal, lawyers would be beating down the door to represent him.

But a new report suggests that Trump is having trouble finding lawyers willing to work for his defense.

  	

Lawyers from at least four major firms — including former Bush solicitor generals Ted Olson, who argued against Proposition 8 in California, and Paul Clement — have turned down White House requests for legal assistance, according to a report by Yahoo News. The “politely declined” list also includes Mark Filip, a former Bush deputy attorney general, and Brendan Sullivan, who represented Oliver North during Iran-Contra hearings.

One of the most common reasons cited was the belief that Trump would not accept his lawyers’ advice and could send out tweets or other public utterances that would undercut his legal teams’ efforts.

While the article didn’t mention this as an example, the concern does draw to mind observations like that of George Washington University Law School Professor Jonathan Turley, who has noted that Trump’s tweets might hurt his lawyers’ case when arguing in support of his so-called travel ban.

“The worst aspect of the tweet is that it plays directly into the hands of those challenging his order,”  Turley noted about Trump’s Monday morning tweetstorm, adding that “it must be incredibly frustrating for his counsel who have insisted that his references to a ‘Muslim ban’ during the campaign are immaterial to the executive order. It does not alter the core of the legal arguments, which I have long stated favor Trump. However, his reference to a ban (which the order is not) undermines the thrust of the arguments raised in courts across the country.”

Lawyers are also concerned that Trump may not listen to their advice or pay them for their time, Yahoo reported. There are also concerns that representing Trump may pose conflicts with some of the firms’ other clients, or that representing Trump will take up more time than they realistically have. Finally, as one lawyer with knowledge of some of the discussions said, there were concerns that being associated with Trump could hurt their reputations: “Do I want to be associated with this president and his policies?”

The lawyers mentioned in these capacities include Paul Clement and Mark Filip of Kirkland & Ellis; Robert Giuffra of Sullivan & Cromwell; Ted Olson of Gibson, Dunn & Crutcher; and Brendan Sullivan of Williams & Connolly.

Matthew Rozsa

Matthew Rozsa is a breaking news writer for Salon. He holds an MA in History from Rutgers University-Newark and his work has appeared in Mic, Quartz and MSNBC.

More Matthew Rozsa.

Go to Source